LNAI — Lunai Bioworks Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1527728 ·
Last close
$1.93
Market Cap
$8.75M
52W High
$13.28
52W Low
$1.21
ADV30
37,993
Next earnings
2026-09-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Mar 2026 20,942 20,942 -1,427,260 -2,571,394 9,860,540 3,155,272 19,413,968
Dec 2025 0 — -1,823,414 -1,799,404 6,666,446 491,645 20,215,234
Sep 2025 0 — -2,476,445 2,819,021 6,960,663 624,808 20,001,437
Jun 2025 0 — -4,113,941 -126,732,236 8,230,840 92,700 29,580,681

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,258,315
Investing CF
$1,507,851
Financing CF
$6,175,226
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-09-06

Balance + Analyst (yfinance extras)

Retained Earnings
$-512,014,347
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-126,637,943
Pretax Income TTM
$-127,197,897
Interest Exp TTM
$559,954
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,942
EBITDA
$-9,769,810
Free Cash Flow
$-6,964,201
Enterprise Value
$9,046,753
Total Cash
$3,155,272
Total Debt
$1,411,367
Shares Out
4,533,890
Trailing EPS
$-61.52
Book Value
$-2.14
ROE
-325.5%
ROA
-9.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2025 0 -18,546,573 -178,007,489 8,230,840 29,580,681 -21,349,841 -7,874,647
Jun 2024 0 -27,388,296 -88,425,828 163,129,450 31,152,306 131,977,144 -10,971,430
Jun 2023 0 -19,596,891 -39,684,056 58,300,796 11,798,685 46,502,111 -11,774,549
Jun 2022 0 -22,826,191 -113,433,392 84,632,663 12,013,815 72,618,848 -15,732,336

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.93 · call volume: 7 · put volume: 100
Expected Move to 2026-10-16: ±$2.23 (115.54%) — implied range $-0.30 – $4.16 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALZN Alzamend Neuro, Inc. $8.83M $1.83 —
TRAW Traws Pharma, Inc. $8.61M $0.56 —
LGVN Longeveron Inc. $8.55M $2.81 —
KALA KALA BIO, Inc. $9.21M $0.48 —
FBLG FibroBiologics, Inc. $9.25M $1.39 —

News headlines (Yahoo Finance, 1h cache)

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
2026-09-22 13:20 · Yahoo
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
2026-09-16 13:25 · Yahoo
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
2026-08-27 13:25 · Yahoo
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
2026-08-04 19:28 · Yahoo
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
2026-08-04 13:20 · Yahoo
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
2026-06-17 13:15 · Yahoo
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
2026-05-06 12:30 · Yahoo
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
2026-05-04 13:35 · Yahoo
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
2026-04-15 13:10 · Yahoo
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
2026-04-07 13:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.